Assessing the economic challenges posed by orphan drugs

Historically, patients with rare diseases have been underserved by commercial drug development. In several jurisdictions, specific legislation has been enacted to encourage the development of drugs for rare diseases (orphan drugs), which would otherwise not be commercially viable. However, because o...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	International journal of technology assessment in health care Ročník 23; číslo 1; s. 36 - 42
Hlavní autoři:	Drummond, Michael F., Wilson, David A., Kanavos, Panos, Ubel, Peter, Rovira, Joan
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	New York, USA Cambridge University Press 01.01.2007
Témata:	Cost analysis Cost-Benefit Analysis Cost-effectiveness analysis Disease Drugs Equity Europe FDA approval GENERAL ESSAYS Health care policy Health Policy Health services Health technology assessment Hospitals Humans Legislation Medical ethics Orphan Drug Production - economics Patients Pharmaceutical industry Rare diseases Reimbursement Support groups Technological change Technology Assessment, Biomedical United States United States Europe Equity Cost-effectiveness analysis Health policy
ISSN:	0266-4623, 1471-6348
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!